Propofol

Drug Profile

Propofol

Alternative Names: Diprivan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class General anaesthetics; Phenols; Small molecules
  • Mechanism of Action GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sedation

Most Recent Events

  • 18 Aug 2017 Aspen Pharmacare completed the transfer of Canadian commercialisation rights associated with propofol from AstraZeneca
  • 06 Jun 2017 Propofol is under regulatory review for Sedation in Japan (IV) (AstraZeneca Annual Report 2016)
  • 09 Jun 2016 Propofol licensed to Aspen for commercialisation worldwide, except USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top